agilon health (AGL) Financials

$4.16 +0.23 (+5.85%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$4.12 -0.04 (-0.84%)

As of 05/2/2025 07:50 PM Eastern

Annual Income Statements for agilon health

This table shows agilon health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-283	-60	-406	-107	-263	-260
Consolidated Net Income / (Loss)	-283	-60	-407	-107	-263	-260
Net Income / (Loss) Continuing Operations	-114	-63	-384	-92	-195	-250
Total Pre-Tax Income	-115	-62	-383	-91	-194	-249
Total Operating Income	-107	-57	-372	-105	-232	-292
Total Gross Profit	794	1,218	66	111	4,316	4.84
Total Revenue	794	1,218	1,521	2,388	4,316	6,061
Operating Revenue	794	1,218	1,521	2,388	4,316	6,061
Total Cost of Revenue	0.00	0.00	1,456	2,277	0.00	6,056
Operating Cost of Revenue	-	-	1,456	2,277	-	6,056
Total Operating Expenses	901	1,275	438	217	4,548	297
Selling, General & Admin Expense	123	137	428	208	286	269
Depreciation Expense	12	14	10	8.95	16	24
Impairment Charge	-	-	-	0.00	0.00	3.60
Total Other Income / (Expense), net	-8.11	-5.67	-11	15	38	43
Interest Expense	9.07	8.14	6.15	4.48	6.66	6.18
Interest & Investment Income	-	0.00	-6.77	11	16	15
Other Income / (Expense), net	0.96	2.47	2.18	8.47	28	34
Income Tax Expense	-0.23	0.87	0.89	1.64	0.79	1.45
Net Income / (Loss) Discontinued Operations	-168	3.16	-23	-15	-68	-9.82
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.15	0.00	-0.30	-0.31	-0.21	0.05
Weighted Average Basic Shares Outstanding	294.74M	323.46M	372.93M	408.15M	408.92M	410.97M
Weighted Average Diluted Shares Outstanding	294.74M	323.46M	372.93M	408.15M	408.92M	410.97M
Weighted Average Basic & Diluted Shares Outstanding	294.74M	323.46M	372.93M	413.12M	409.54M	412.30M

This table shows agilon health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-31	-12	16	-17	-31	-230	-6.06	-31	-118	-106
Consolidated Net Income / (Loss)	-31	-57	16	-17	-31	-230	-6.03	-31	-118	-106
Net Income / (Loss) Continuing Operations	-31	-41	9.95	-16	-22	-167	3.25	-31	-116	-106
Total Pre-Tax Income	-30	3.81	8.19	-15	-21	-167	3.11	-30	-117	-105
Total Operating Income	-30	-12	0.42	-29	-39	-164	-7.18	-43	-134	-108
Total Gross Profit	26	-585	1,054	55	37	3,171	1,604	32	-64	-1,568
Total Revenue	695	1,023	1,054	1,069	1,137	1,056	1,604	1,483	1,451	1,522
Operating Revenue	695	-	1,054	1,069	1,137	1,056	1,604	1,483	1,451	1,522
Total Cost of Revenue	669	1,608	0.00	1,015	1,100	-2,115	0.00	1,451	1,515	3,090
Total Operating Expenses	55	-1,184	1,054	84	76	3,335	1,612	76	69	-1,459
Selling, General & Admin Expense	52	64	70	79	72	65	76	70	63	60
Depreciation Expense	3.45	-0.92	2.95	4.28	4.08	4.74	5.84	5.91	6.22	6.49
Total Other Income / (Expense), net	-0.43	15	7.78	14	18	-2.57	10	13	16	3.43
Interest Expense	1.00	1.67	1.49	1.56	1.62	1.99	1.28	1.70	1.62	1.57
Interest & Investment Income	-4.31	-	1.38	8.47	15	-8.02	5.68	9.96	2.05	-2.69
Other Income / (Expense), net	4.89	-	7.89	7.09	5.42	7.44	5.89	4.84	16	7.70
Income Tax Expense	0.56	0.57	-1.76	1.07	1.21	0.27	-0.13	0.42	-0.59	1.76
Net Income / (Loss) Discontinued Operations	-0.24	-15	6.01	-0.77	-9.44	-63	-9.28	0.00	-1.18	0.64
Weighted Average Basic Shares Outstanding	411.07M	408.15M	413.14M	410.34M	405.79M	408.92M	408.94M	411.27M	411.59M	410.97M
Weighted Average Diluted Shares Outstanding	411.07M	408.15M	426.59M	410.34M	405.79M	408.92M	413.44M	411.27M	411.59M	410.97M
Weighted Average Basic & Diluted Shares Outstanding	411.85M	413.12M	414.83M	405.48M	406.04M	409.54M	411.26M	411.48M	412.02M	412.30M

This table details how cash moves in and out of agilon health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	67	-6.52	916	-547	-393	80
Net Cash From Operating Activities	-104	-53	-148	-131	-156	-58
Net Cash From Continuing Operating Activities	-104	-12	-148	-131	-156	-58
Net Income / (Loss) Continuing Operations	-283	-60	-407	-107	-263	-260
Consolidated Net Income / (Loss)	-283	-60	-407	-107	-263	-260
Depreciation Expense	41	14	15	14	20	24
Non-Cash Adjustments To Reconcile Net Income	120	30	302	21	97	47
Changes in Operating Assets and Liabilities, net	17	3.66	-58	-59	-10	131
Net Cash From Investing Activities	-5.06	22	-91	-444	-44	140
Net Cash From Continuing Investing Activities	-5.06	22	-91	-444	-44	140
Purchase of Property, Plant & Equipment	-2.89	-1.78	-6.56	-15	-16	-13
Acquisitions	-1.01	-0.58	-6.86	-17	-60	-28
Purchase of Investments	-	0.00	0.00	-458	-115	-12
Divestitures	0.00	26	-1.34	0.50	2.19	0.00
Sale and/or Maturity of Investments	-	2.06	7.10	53	164	207
Other Investing Activities, net	-1.15	-3.85	-83	-6.51	-20	-14
Net Cash From Financing Activities	176	25	1,154	28	-193	-2.58
Net Cash From Continuing Financing Activities	176	25	1,154	28	-193	-2.58
Repayment of Debt	-3.59	-3.04	-135	-5.00	-5.00	-3.75
Repurchase of Common Equity	0.00	-6.74	0.00	0.00	-200	0.00
Issuance of Common Equity	180	34	1,189	33	12	1.17

This table details how cash moves in and out of agilon health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-119	-57	-103	-203	-23	-64	4.22	-2.21	37	40
Net Cash From Operating Activities	2.65	-50	-61	-21	-13	-61	-48	-19	-7.70	16
Net Cash From Continuing Operating Activities	2.65	-50	-61	-21	-13	-61	-48	-19	-7.70	16
Net Income / (Loss) Continuing Operations	-31	-57	16	-17	-31	-230	-6.03	-31	-118	-106
Consolidated Net Income / (Loss)	-31	-57	16	-17	-31	-230	-6.03	-31	-118	-106
Depreciation Expense	3.45	3.91	4.19	5.52	5.31	5.15	5.84	5.91	6.22	6.49
Non-Cash Adjustments To Reconcile Net Income	13	1.97	11	11	6.89	69	16	10	12	9.95
Changes in Operating Assets and Liabilities, net	17	0.71	-91	-20	6.27	96	-63	-3.98	92	106
Net Cash From Investing Activities	-131	-7.97	-51	20	-11	-2.20	51	18	47	24
Net Cash From Continuing Investing Activities	-131	-7.97	-51	20	-11	-2.20	51	18	47	24
Purchase of Property, Plant & Equipment	-3.43	-3.49	-3.72	-4.09	-4.09	-3.93	-3.14	-3.31	-3.53	-3.27
Acquisitions	-0.25	-4.82	-44	-1.84	-1.81	-12	-11	-6.46	-0.98	-9.16
Sale and/or Maturity of Investments	11	37	29	69	37	30	75	41	51	40
Other Investing Activities, net	-	-2.00	-1.30	-7.17	-0.31	-11	-8.51	-1.23	-	-3.99
Net Cash From Financing Activities	9.11	1.13	8.34	-202	1.41	-0.85	0.56	-1.71	-1.41	-0.02
Net Cash From Continuing Financing Activities	9.11	1.13	8.34	-202	1.41	-0.85	0.56	-1.71	-1.41	-0.02
Issuance of Common Equity	10	2.38	9.59	-0.79	2.66	0.41	1.81	-0.46	-0.16	-0.02

This table presents agilon health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	446	1,586	1,697	1,741	1,734
Total Current Assets	294	1,367	1,451	1,480	1,458
Cash & Equivalents	107	1,040	465	108	188
Restricted Cash	-	15	11	6.76	5.63
Short-Term Investments	-	0.00	412	381	212
Accounts Receivable	145	293	492	942	1,017
Prepaid Expenses	9.64	19	32	43	35
Plant, Property, & Equipment, net	6.46	9.16	20	28	28
Total Noncurrent Assets	146	210	226	233	248
Goodwill	42	42	2.51	24	24
Intangible Assets	60	55	18	64	73
Other Noncurrent Operating Assets	44	113	106	145	151
Total Liabilities & Shareholders' Equity	446	1,586	1,697	1,741	1,734
Total Liabilities	422	495	657	1,080	1,263
Total Current Liabilities	267	357	535	977	1,152
Accounts Payable	97	113	177	239	220
Other Current Liabilities	163	239	301	738	932
Total Noncurrent Liabilities	155	138	122	103	111
Long-Term Debt	65	43	38	32	35
Other Noncurrent Operating Liabilities	90	94	82	70	76
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-285	1,092	1,041	661	471
Total Preferred & Common Equity	-285	1,092	1,041	662	471
Total Common Equity	-285	1,092	1,041	662	471
Common Stock	266	2,050	2,111	1,991	2,058
Retained Earnings	-551	-958	-1,064	-1,327	-1,587
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-5.56	-2.30	-0.09
Noncontrolling Interest	0.00	-0.30	-0.61	-0.82	0.00

This table presents agilon health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,870	2,170	2,353	2,278	2,316	2,163	2,091
Total Current Assets	1,634	1,876	2,045	1,957	2,037	1,884	1,812
Cash & Equivalents	551	394	191	168	112	109	148
Restricted Cash	-	10	10	10	6.84	6.85	5.63
Short-Term Investments	408	422	389	396	307	292	245
Accounts Receivable	638	1,005	1,417	1,346	1,571	1,437	1,368
Prepaid Expenses	24	45	38	37	40	39	45
Plant, Property, & Equipment, net	18	22	24	26	28	28	28
Total Noncurrent Assets	218	272	284	295	252	251	251
Goodwill	42	62	62	62	24	24	24
Intangible Assets	61	93	94	93	72	75	73
Other Noncurrent Operating Assets	116	117	127	140	156	153	154
Total Liabilities & Shareholders' Equity	1,870	2,170	2,353	2,278	2,316	2,163	2,091
Total Liabilities	785	1,088	1,473	1,406	1,628	1,487	1,517
Total Current Liabilities	658	973	1,362	1,301	1,527	1,387	1,409
Accounts Payable	162	222	258	291	252	281	218
Other Current Liabilities	491	746	1,100	1,006	1,267	1,098	1,191
Total Noncurrent Liabilities	127	116	111	105	101	100	107
Long-Term Debt	40	37	36	35	30	27	35
Other Noncurrent Operating Liabilities	87	79	75	70	71	73	72
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,085	1,082	879	872	688	676	575
Total Preferred & Common Equity	1,086	1,083	880	872	689	677	575
Total Common Equity	1,086	1,083	880	872	689	677	575
Common Stock	2,099	2,134	1,951	1,975	2,025	2,043	2,056
Retained Earnings	-1,008	-1,048	-1,065	-1,096	-1,333	-1,364	-1,481
Accumulated Other Comprehensive Income / (Loss)	-5.10	-3.55	-6.37	-6.23	-2.75	-2.45	0.30
Noncontrolling Interest	-0.53	-0.67	-0.72	-0.77	-0.79	-0.77	0.00

This table displays calculated financial ratios and metrics derived from agilon health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	53.36%	24.88%	56.97%	80.74%	40.41%
EBITDA Growth	0.00%	37.53%	-786.07%	76.61%	-121.49%	-26.64%
EBIT Growth	0.00%	48.68%	-582.67%	73.81%	-110.82%	-26.11%
NOPAT Growth	0.00%	46.82%	-556.82%	71.69%	-120.29%	-25.85%
Net Income Growth	0.00%	78.76%	-577.39%	73.73%	-145.92%	1.03%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	48.77%	-178.47%	11.71%	-19.41%	63.01%
Free Cash Flow Firm Growth	0.00%	0.00%	-1,392.04%	72.71%	-154.39%	57.52%
Invested Capital Growth	0.00%	0.00%	650.88%	29.12%	80.24%	-49.42%
Revenue Q/Q Growth	0.00%	0.00%	-10.06%	57.55%	0.77%	8.34%
EBITDA Q/Q Growth	0.00%	0.00%	2.40%	21.89%	-204.28%	19.86%
EBIT Q/Q Growth	0.00%	0.00%	2.33%	19.20%	-157.18%	17.97%
NOPAT Q/Q Growth	0.00%	0.00%	3.52%	12.14%	-192.23%	16.13%
Net Income Q/Q Growth	0.00%	0.00%	-8.69%	0.18%	-195.72%	32.41%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-31.58%	-0.82%	-7.73%	57.32%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	43.20%	-13.03%	9.78%
Invested Capital Q/Q Growth	0.00%	0.00%	4.94%	-35.58%	-41.17%	-52.53%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	4.32%	4.66%	100.00%	0.08%
EBITDA Margin	-8.08%	-3.29%	-23.36%	-3.48%	-4.27%	-3.85%
Operating Margin	-13.42%	-4.65%	-24.47%	-4.41%	-5.38%	-4.82%
EBIT Margin	-13.30%	-4.45%	-24.32%	-4.06%	-4.73%	-4.25%
Profit (Net Income) Margin	-35.59%	-4.93%	-26.74%	-4.47%	-6.09%	-4.29%
Tax Burden Percent	246.53%	96.33%	106.22%	117.86%	135.14%	104.53%
Interest Burden Percent	108.59%	115.01%	103.49%	93.56%	95.19%	96.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-747.53%	-75.60%	-105.45%	-137.02%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-719.59%	-72.18%	-91.05%	-123.67%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	674.65%	65.57%	74.56%	91.06%
Return on Equity (ROE)	0.00%	-242.44%	-72.88%	-10.02%	-30.89%	-45.96%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-424.07%	-101.01%	-162.71%	-71.38%
Operating Return on Assets (OROA)	0.00%	-12.14%	-36.41%	-5.90%	-11.88%	-14.83%
Return on Assets (ROA)	0.00%	-13.45%	-40.03%	-6.51%	-15.29%	-14.97%
Return on Common Equity (ROCE)	0.00%	2,786.82%	-52.69%	-10.03%	-30.91%	-45.99%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.09%	-37.26%	-10.26%	-39.71%	-55.23%
Net Operating Profit after Tax (NOPAT)	-75	-40	-261	-74	-162	-204
NOPAT Margin	-9.39%	-3.26%	-17.13%	-3.09%	-3.76%	-3.37%
Net Nonoperating Expense Percent (NNEP)	0.00%	-101.32%	-27.94%	-3.42%	-14.40%	-13.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-6.80%	-23.44%	-40.42%
Cost of Revenue to Revenue	0.00%	0.00%	95.68%	95.34%	0.00%	99.92%
SG&A Expenses to Revenue	15.46%	11.27%	28.10%	8.70%	6.62%	4.44%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	113.42%	104.65%	28.79%	9.08%	105.38%	4.90%
Earnings before Interest and Taxes (EBIT)	-106	-54	-370	-97	-204	-258
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-40	-355	-83	-184	-233
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	9.73	6.38	7.70	1.66
Price to Tangible Book Value (P/TBV)	0.00	0.00	10.68	6.52	8.88	2.09
Price to Revenue (P/Rev)	1.35	0.88	6.99	2.78	1.18	0.13
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	112.96	52.76	23.37	4.11
Enterprise Value to Revenue (EV/Rev)	0.00	1.10	6.32	2.43	1.07	0.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	2.73	0.04	0.04	0.05	0.07
Long-Term Debt to Equity	0.00	2.61	0.04	0.04	0.05	0.07
Financial Leverage	0.00	-1.62	-0.94	-0.91	-0.82	-0.74
Leverage Ratio	0.00	18.02	1.82	1.54	2.02	3.07
Compound Leverage Factor	0.00	20.72	1.88	1.44	1.92	2.96
Debt to Total Capital	0.00%	73.21%	4.25%	4.01%	4.66%	6.90%
Short-Term Debt to Total Capital	0.00%	3.29%	0.44%	0.46%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	69.93%	3.81%	3.55%	4.66%	6.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	334.68%	-0.03%	-0.06%	-0.12%	0.00%
Common Equity to Total Capital	0.00%	-307.90%	95.78%	96.05%	95.46%	93.10%
Debt to EBITDA	0.00	-1.69	-0.14	-0.52	-0.18	-0.15
Net Debt to EBITDA	0.00	0.97	2.83	10.16	2.51	1.59
Long-Term Debt to EBITDA	0.00	-1.61	-0.12	-0.46	-0.18	-0.15
Debt to NOPAT	0.00	-1.71	-0.19	-0.59	-0.20	-0.17
Net Debt to NOPAT	0.00	0.99	3.86	11.45	2.85	1.81
Long-Term Debt to NOPAT	0.00	-1.63	-0.17	-0.52	-0.20	-0.17
Altman Z-Score	0.00	2.20	13.00	7.06	4.20	2.31
Noncontrolling Interest Sharing Ratio	0.00%	1,249.50%	27.70%	-0.04%	-0.08%	-0.07%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	1.10	3.83	2.71	1.51	1.27
Quick Ratio	0.00	0.94	3.74	2.56	1.46	1.23
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-24	-361	-99	-251	-107
Operating Cash Flow to CapEx	-3,591.32%	-2,997.41%	-2,257.15%	-847.97%	-986.73%	-436.02%
Free Cash Flow to Firm to Interest Expense	0.00	-2.98	-58.77	-21.98	-37.66	-17.25
Operating Cash Flow to Interest Expense	-11.45	-6.54	-24.11	-29.17	-23.46	-9.35
Operating Cash Flow Less CapEx to Interest Expense	-11.77	-6.76	-25.17	-32.61	-25.84	-11.50
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	2.73	1.50	1.45	2.51	3.49
Accounts Receivable Turnover	0.00	8.43	6.95	6.08	6.02	6.19
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	188.71	194.85	164.15	181.69	217.44
Accounts Payable Turnover	0.00	0.00	13.85	15.68	0.00	26.34
Days Sales Outstanding (DSO)	0.00	43.31	52.53	60.05	60.67	59.01
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	26.35	23.27	0.00	13.86
Cash Conversion Cycle (CCC)	0.00	43.31	26.18	36.77	60.67	45.15
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	-15	85	110	198	100
Invested Capital Turnover	0.00	-157.59	43.65	24.48	28.01	40.61
Increase / (Decrease) in Invested Capital	0.00	-15	101	25	88	-98
Enterprise Value (EV)	0.00	1,342	9,622	5,802	4,632	412
Market Capitalization	1,072	1,072	10,629	6,647	5,096	783
Book Value per Share	$0.00	($0.88)	$2.77	$2.53	$1.63	$1.14
Tangible Book Value per Share	$0.00	($1.20)	$2.53	$2.48	$1.41	$0.91
Total Capital	0.00	92	1,140	1,084	693	506
Total Debt	0.00	68	48	43	32	35
Total Long-Term Debt	0.00	65	43	38	32	35
Net Debt	0.00	-39	-1,006	-844	-463	-371
Capital Expenditures (CapEx)	2.89	1.78	6.56	15	16	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-76	-40	33	7.82	-100
Debt-free Net Working Capital (DFNWC)	0.00	30	1,015	921	503	306
Net Working Capital (NWC)	0.00	27	1,010	916	503	306
Net Nonoperating Expense (NNE)	208	20	146	33	100	56
Net Nonoperating Obligations (NNO)	0.00	-40	-1,006	-931	-463	-371
Total Depreciation and Amortization (D&A)	41	14	15	14	20	24
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-6.27%	-2.60%	1.40%	0.18%	-1.65%
Debt-free Net Working Capital to Revenue	0.00%	2.50%	66.73%	38.57%	11.65%	5.05%
Net Working Capital to Revenue	0.00%	2.25%	66.40%	38.36%	11.65%	5.05%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	401.18M	408.15M	408.92M	410.97M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	401.18M	408.15M	408.92M	410.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	372.93M	413.12M	409.54M	412.30M
Normalized Net Operating Profit after Tax (NOPAT)	-75	-40	-261	-74	-162	-202
Normalized NOPAT Margin	-9.39%	-3.26%	-17.13%	-3.09%	-3.76%	-3.33%
Pre Tax Income Margin	-14.44%	-5.12%	-25.17%	-3.80%	-4.51%	-4.11%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-11.65	-6.66	-60.21	-21.61	-30.68	-41.71
NOPAT to Interest Expense	-8.23	-4.88	-42.40	-16.45	-24.41	-33.11
EBIT Less CapEx to Interest Expense	-11.97	-6.88	-61.28	-25.05	-33.06	-43.85
NOPAT Less CapEx to Interest Expense	-8.55	-5.09	-43.46	-19.89	-26.78	-35.25
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	-0.11%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.11%	-11.23%	0.00%	0.00%	-76.10%	0.00%

This table displays calculated financial ratios and metrics derived from agilon health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	51.51%	578.44%	0.00%	59.54%	63.61%	3.21%	52.17%	38.69%	27.63%	44.16%
EBITDA Growth	33.67%	68.44%	131.38%	-48.51%	-34.85%	-1,871.85%	-63.53%	-99.30%	-289.44%	38.10%
EBIT Growth	31.34%	58.60%	119.23%	-55.60%	-37.52%	-1,252.13%	-115.48%	-76.05%	-246.75%	35.99%
NOPAT Growth	17.09%	46.17%	101.67%	-37.55%	-33.12%	-1,066.50%	-1,577.59%	-49.68%	-239.77%	34.21%
Net Income Growth	14.51%	0.33%	1,281.73%	18.99%	-2.42%	-307.58%	-137.81%	-82.57%	-273.58%	54.10%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	113.83%	-2.17%	-161.74%	64.81%	-591.80%	-22.43%	21.44%	11.73%	40.83%	126.84%
Free Cash Flow Firm Growth	-3.90%	70.86%	9.18%	-41.29%	-75.78%	-486.45%	93.62%	97.58%	116.67%	110.97%
Invested Capital Growth	110.34%	29.12%	117.10%	83.40%	97.37%	80.24%	0.91%	-7.94%	-37.32%	-49.42%
Revenue Q/Q Growth	3.69%	47.26%	3.04%	1.40%	6.34%	-7.11%	64.17%	-7.58%	-2.15%	4.93%
EBITDA Q/Q Growth	-92.32%	63.67%	262.44%	-230.86%	-74.63%	-431.19%	103.20%	-815.14%	-241.24%	15.57%
EBIT Q/Q Growth	-75.24%	52.90%	171.62%	-363.21%	-54.87%	-363.11%	99.13%	-2,894.01%	-205.03%	14.51%
NOPAT Q/Q Growth	-40.21%	52.28%	105.14%	-4,101.65%	-35.70%	-318.13%	93.08%	-305.38%	-208.02%	19.03%
Net Income Q/Q Growth	-48.28%	-83.97%	128.22%	-205.24%	-87.45%	-632.09%	97.38%	-408.15%	-283.59%	10.05%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	104.39%	-1,987.38%	-21.72%	65.13%	38.61%	-369.86%	21.89%	60.82%	58.84%	313.15%
Free Cash Flow Firm Q/Q Growth	8.63%	68.55%	-361.06%	-6.66%	-13.67%	-4.91%	94.97%	59.50%	882.58%	-30.97%
Invested Capital Q/Q Growth	-5.19%	-35.58%	170.24%	11.11%	2.04%	-41.17%	46.67%	1.37%	-30.53%	-52.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	3.73%	-57.14%	100.00%	5.10%	3.24%	300.23%	100.00%	2.17%	-4.42%	-102.96%
EBITDA Margin	-3.05%	-0.75%	1.19%	-1.53%	-2.51%	-14.37%	0.28%	-2.20%	-7.67%	-6.17%
Operating Margin	-4.25%	-1.13%	0.04%	-2.71%	-3.46%	-15.56%	-0.45%	-2.92%	-9.20%	-7.10%
EBIT Margin	-3.54%	-1.13%	0.79%	-2.05%	-2.98%	-14.85%	-0.08%	-2.60%	-8.09%	-6.59%
Profit (Net Income) Margin	-4.42%	-5.53%	1.51%	-1.57%	-2.77%	-21.82%	-0.38%	-2.07%	-8.11%	-6.95%
Tax Burden Percent	102.66%	-1,484.23%	194.81%	112.32%	151.15%	138.12%	-193.77%	101.38%	100.51%	101.07%
Interest Burden Percent	121.58%	-32.84%	98.59%	68.37%	61.50%	106.38%	-242.15%	78.55%	99.64%	104.25%
Effective Tax Rate	0.00%	15.01%	-21.47%	0.00%	0.00%	0.00%	-4.27%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-35.79%	-23.58%	0.76%	-28.55%	-40.83%	-305.03%	-7.60%	-34.07%	-131.47%	-201.83%
ROIC Less NNEP Spread (ROIC-NNEP)	-34.76%	-18.76%	-0.99%	-29.02%	-40.28%	-288.46%	-7.85%	-34.00%	-126.09%	-194.60%
Return on Net Nonoperating Assets (RNNOA)	30.81%	17.05%	0.80%	21.55%	29.83%	236.21%	5.20%	20.13%	78.30%	143.29%
Return on Equity (ROE)	-4.98%	-6.54%	1.56%	-7.00%	-11.00%	-68.82%	-2.40%	-13.93%	-53.16%	-58.54%
Cash Return on Invested Capital (CROIC)	-137.77%	-101.01%	-93.77%	-77.97%	-87.39%	-162.71%	-57.11%	-47.83%	-43.08%	-71.38%
Operating Return on Assets (OROA)	-3.02%	-1.65%	1.35%	-3.75%	-6.15%	-37.29%	-0.17%	-6.07%	-20.73%	-23.00%
Return on Assets (ROA)	-3.77%	-8.04%	2.59%	-2.88%	-5.72%	-54.80%	-0.82%	-4.84%	-20.76%	-24.24%
Return on Common Equity (ROCE)	-4.99%	-6.54%	1.56%	-7.00%	-11.01%	-68.88%	-2.40%	-13.95%	-53.19%	-58.58%
Return on Equity Simple (ROE_SIMPLE)	-9.86%	0.00%	-8.50%	-10.01%	-10.19%	0.00%	-41.32%	-44.14%	-66.94%	0.00%
Net Operating Profit after Tax (NOPAT)	-21	-9.86	0.51	-20	-28	-115	-7.48	-30	-93	-76
NOPAT Margin	-2.97%	-0.96%	0.05%	-1.90%	-2.42%	-10.89%	-0.47%	-2.05%	-6.44%	-4.97%
Net Nonoperating Expense Percent (NNEP)	-1.03%	-4.82%	1.76%	0.47%	-0.55%	-16.57%	0.25%	-0.07%	-5.38%	-7.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.91%	-	-	-	-16.59%	-	-	-	-14.96%
Cost of Revenue to Revenue	96.27%	157.14%	0.00%	94.90%	96.76%	-200.23%	0.00%	97.83%	104.42%	202.96%
SG&A Expenses to Revenue	7.48%	6.26%	6.62%	7.41%	6.34%	6.13%	4.76%	4.69%	4.35%	3.92%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	7.98%	-115.72%	99.96%	7.81%	6.70%	315.79%	100.45%	5.09%	4.78%	-95.86%
Earnings before Interest and Taxes (EBIT)	-25	-12	8.31	-22	-34	-157	-1.29	-39	-117	-100
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-7.69	12	-16	-29	-152	4.56	-33	-111	-94
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.86	6.38	9.06	8.17	8.26	7.70	3.59	3.98	2.81	1.66
Price to Tangible Book Value (P/TBV)	9.78	6.52	10.58	9.94	10.04	8.88	4.18	4.66	3.39	2.09
Price to Revenue (P/Rev)	6.35	2.78	2.85	1.87	1.68	1.18	0.51	0.51	0.29	0.13
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	51.01	52.76	30.37	20.12	19.78	23.37	6.96	7.62	5.93	4.11
Enterprise Value to Revenue (EV/Rev)	5.75	2.43	2.62	1.73	1.56	1.07	0.43	0.44	0.22	0.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.04	0.04	0.05	0.05	0.05	0.05	0.05	0.06	0.07
Long-Term Debt to Equity	0.04	0.04	0.03	0.04	0.04	0.05	0.04	0.04	0.06	0.07
Financial Leverage	-0.89	-0.91	-0.80	-0.74	-0.74	-0.82	-0.66	-0.59	-0.62	-0.74
Leverage Ratio	1.61	1.54	1.84	2.11	2.12	2.02	2.53	2.90	3.02	3.07
Compound Leverage Factor	1.95	-0.51	1.81	1.45	1.30	2.15	-6.14	2.28	3.01	3.20
Debt to Total Capital	3.96%	4.01%	3.76%	4.46%	4.36%	4.66%	5.14%	5.07%	5.72%	6.90%
Short-Term Debt to Total Capital	0.44%	0.46%	0.44%	0.54%	0.55%	0.00%	1.03%	1.23%	0.00%	0.00%
Long-Term Debt to Total Capital	3.51%	3.55%	3.31%	3.91%	3.82%	4.66%	4.11%	3.84%	5.72%	6.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.05%	-0.06%	-0.06%	-0.08%	-0.08%	-0.12%	-0.11%	-0.11%	0.00%	0.00%
Common Equity to Total Capital	96.09%	96.05%	96.30%	95.62%	95.72%	95.46%	94.96%	95.04%	94.28%	93.10%
Debt to EBITDA	-0.42	-0.52	-0.90	-0.78	-0.66	-0.18	-0.19	-0.17	-0.12	-0.15
Net Debt to EBITDA	8.59	10.16	16.64	10.44	8.84	2.51	2.02	1.79	1.25	1.59
Long-Term Debt to EBITDA	-0.37	-0.46	-0.79	-0.68	-0.57	-0.18	-0.16	-0.13	-0.12	-0.15
Debt to NOPAT	-0.53	-0.59	-0.98	-0.84	-0.72	-0.20	-0.22	-0.20	-0.14	-0.17
Net Debt to NOPAT	10.89	11.45	18.15	11.26	9.62	2.85	2.32	2.09	1.49	1.81
Long-Term Debt to NOPAT	-0.47	-0.52	-0.86	-0.74	-0.63	-0.20	-0.18	-0.15	-0.14	-0.17
Altman Z-Score	7.99	7.23	6.83	4.25	4.57	4.29	2.47	2.86	2.37	2.61
Noncontrolling Interest Sharing Ratio	-0.04%	-0.04%	-0.05%	-0.06%	-0.07%	-0.08%	-0.08%	-0.10%	-0.05%	-0.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.48	2.71	1.93	1.50	1.50	1.51	1.33	1.36	1.29	1.27
Quick Ratio	2.43	2.56	1.87	1.47	1.47	1.46	1.30	1.33	1.25	1.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-110	-35	-160	-170	-194	-203	-10	-4.13	32	22
Operating Cash Flow to CapEx	77.10%	-1,431.90%	-1,636.02%	-517.93%	-318.52%	-1,555.60%	-1,522.01%	-565.13%	-217.97%	502.73%
Free Cash Flow to Firm to Interest Expense	-110.22	-20.78	-107.03	-109.61	-119.82	-101.99	-7.94	-2.43	19.92	14.17
Operating Cash Flow to Interest Expense	2.65	-29.95	-40.73	-13.64	-8.05	-30.69	-37.21	-11.03	-4.75	10.43
Operating Cash Flow Less CapEx to Interest Expense	-0.79	-32.04	-43.22	-16.27	-10.58	-32.66	-39.65	-12.98	-6.93	8.36
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.85	1.45	1.71	1.83	2.07	2.51	2.17	2.34	2.56	3.49
Accounts Receivable Turnover	3.09	6.08	4.37	3.79	4.32	6.02	3.78	3.70	4.12	6.19
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	124.24	164.15	198.66	191.05	194.07	181.69	195.95	202.19	205.68	217.44
Accounts Payable Turnover	6.22	15.68	0.00	5.07	6.38	0.00	0.00	1.62	3.34	26.34
Days Sales Outstanding (DSO)	118.02	60.05	83.59	96.19	84.50	60.67	96.61	98.65	88.54	59.01
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	58.72	23.27	0.00	71.93	57.18	0.00	0.00	225.47	109.15	13.86
Cash Conversion Cycle (CCC)	59.30	36.77	83.59	24.26	27.32	60.67	96.61	-126.82	-20.61	45.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	171	110	297	330	337	198	300	304	211	100
Invested Capital Turnover	12.04	24.48	15.86	15.06	16.87	28.01	16.30	16.65	20.41	40.61
Increase / (Decrease) in Invested Capital	90	25	160	150	166	88	2.71	-26	-126	-98
Enterprise Value (EV)	8,709	5,802	9,026	6,643	6,666	4,632	2,087	2,317	1,253	412
Market Capitalization	9,624	6,647	9,812	7,193	7,201	5,096	2,477	2,690	1,617	783
Book Value per Share	$2.64	$2.53	$2.62	$2.12	$2.15	$1.63	$1.69	$1.65	$1.40	$1.14
Tangible Book Value per Share	$2.39	$2.48	$2.25	$1.74	$1.77	$1.41	$1.45	$1.40	$1.16	$0.91
Total Capital	1,130	1,084	1,124	920	911	693	726	712	610	506
Total Debt	45	43	42	41	40	32	37	36	35	35
Total Long-Term Debt	40	38	37	36	35	32	30	27	35	35
Net Debt	-915	-844	-785	-549	-535	-463	-389	-372	-364	-371
Capital Expenditures (CapEx)	3.43	3.49	3.72	4.09	4.09	3.93	3.14	3.31	3.53	3.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	33	82	97	86	7.82	92	97	4.05	-100
Debt-free Net Working Capital (DFNWC)	981	921	909	687	660	503	518	505	403	306
Net Working Capital (NWC)	976	916	904	682	655	503	510	497	403	306
Net Nonoperating Expense (NNE)	10	47	-15	-3.47	3.98	115	-1.45	0.32	24	30
Net Nonoperating Obligations (NNO)	-915	-931	-785	-549	-535	-463	-389	-372	-364	-371
Total Depreciation and Amortization (D&A)	3.45	3.91	4.19	5.52	5.31	5.15	5.84	5.91	6.22	6.49
Debt-free, Cash-free Net Working Capital to Revenue	1.44%	1.40%	2.38%	2.53%	2.01%	0.18%	1.89%	1.85%	0.07%	-1.65%
Debt-free Net Working Capital to Revenue	64.72%	38.57%	26.40%	17.90%	15.42%	11.65%	10.64%	9.57%	7.20%	5.05%
Net Working Capital to Revenue	64.39%	38.36%	26.25%	17.77%	15.30%	11.65%	10.48%	9.41%	7.20%	5.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	411.07M	408.15M	413.14M	410.34M	405.79M	408.92M	408.94M	411.27M	411.59M	410.97M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	411.07M	408.15M	426.59M	410.34M	405.79M	408.92M	413.44M	411.27M	411.59M	410.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	411.85M	413.12M	414.83M	405.48M	406.04M	409.54M	411.26M	411.48M	412.02M	412.30M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-9.86	0.29	-20	-28	-115	-5.02	-30	-93	-76
Normalized NOPAT Margin	-2.97%	-0.96%	0.03%	-1.90%	-2.42%	-10.89%	-0.31%	-2.05%	-6.44%	-4.97%
Pre Tax Income Margin	-4.31%	0.37%	0.78%	-1.40%	-1.83%	-15.80%	0.19%	-2.04%	-8.07%	-6.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-24.63	-6.96	5.57	-14.06	-20.95	-78.71	-1.00	-22.69	-72.41	-63.79
NOPAT to Interest Expense	-20.66	-5.91	0.34	-13.04	-17.01	-57.71	-5.83	-17.88	-57.62	-48.08
EBIT Less CapEx to Interest Expense	-28.06	-9.05	3.08	-16.70	-23.47	-80.68	-3.45	-24.64	-74.59	-65.86
NOPAT Less CapEx to Interest Expense	-24.10	-8.00	-2.15	-15.67	-19.54	-59.68	-8.27	-19.83	-59.80	-50.15
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	9.27%	0.00%	0.00%	-226.95%	-225.05%	-76.10%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About agilon health's Financials

When does agilon health's financial year end?

According to the most recent income statement we have on file, agilon health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has agilon health's net income changed over the last 5 years?

agilon health's net income appears to be on an upward trend, with a most recent value of -$260.10 million in 2024, falling from -$282.74 million in 2019. The previous period was -$262.80 million in 2023. View agilon health's forecast to see where analysts expect agilon health to go next.

What is agilon health's operating income?

agilon health's total operating income in 2024 was -$292.13 million, based on the following breakdown:

Total Gross Profit: $4.84 million
Total Operating Expenses: $296.97 million

How has agilon health revenue changed over the last 5 years?

Over the last 5 years, agilon health's total revenue changed from $794.41 million in 2019 to $6.06 billion in 2024, a change of 662.9%.

How much debt does agilon health have?

agilon health's total liabilities were at $1.26 billion at the end of 2024, a 17.0% increase from 2023, and a 199.6% increase since 2020.

How much cash does agilon health have?

In the past 4 years, agilon health's cash and equivalents has ranged from $106.80 million in 2020 to $1.04 billion in 2021, and is currently $188.23 million as of their latest financial filing in 2024.

How has agilon health's book value per share changed over the last 5 years?

Over the last 5 years, agilon health's book value per share changed from 0.00 in 2019 to 1.14 in 2024, a change of 114.3%.

Related Companies

This page (NYSE:AGL) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

agilon health (AGL) Financials

Frequently Asked Questions About agilon health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

agilon health (AGL) Financials

Annual Income Statements for agilon health

Quarterly Income Statements for agilon health

Annual Cash Flow Statements for agilon health

Quarterly Cash Flow Statements for agilon health

Annual Balance Sheets for agilon health

Quarterly Balance Sheets for agilon health

Annual Metrics and Ratios for agilon health

Quarterly Metrics and Ratios for agilon health

Frequently Asked Questions About agilon health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools